Homologous-targeting biomimetic nanoparticles co-loaded with melittin and a photosensitizer for the combination therapy of triple negative breast cancer-Reference-Cited by-同舟云学术

Homologous-targeting biomimetic nanoparticles co-loaded with melittin and a photosensitizer for the combination therapy of triple negative breast cancer

Published:2024 Issue:22 Volume:12 Page:5465-5478
ISSN:2050-750X
Container-title:Journal of Materials Chemistry B
language:en
Short-container-title:J. Mater. Chem. B

Author:

Zhang Tao¹²,Bai Liya¹,You Ran¹,Yang Meng¹,Chen Qian¹,Cheng Yuanyuan¹,Qian Zhanyin¹,Wang Yinsong¹^ORCID,Liu Yuanyuan¹^ORCID

Affiliation:

1. Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy; Department of Genetics, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China

2. Department of Pharmacy, Tianjin First Central Hospital, Tianjin 300192, China

Abstract

Melittin (Mel) is considered a promising candidate drug for the treatment of triple negative breast cancer (TNBC) due to its various antitumor effects.

Funder

National Natural Science Foundation of China

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/TB/D3TB02919K

Reference34 articles.

1. Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer

2. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

3. Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment

4. Recent treatment progress of triple negative breast cancer

5. The role of the NDRG1 in the pathogenesis and treatment of breast cancer